Last 12 months
Inside the activity.
1 purchase rows · 24 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 2 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 30, 2020 Filed Jul 31, 2020 22:51 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,254 | $26.06 | $110,859.24 |
DisclosureSEC source: 0001209191-20-044313 · doc4.xml · nonDerivative · entry 8 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 714,746 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.31 to $26.30, inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 22:51 UTC |
Payson NormanDirector
|
SaleCommon Stock | 327 | $26.34 | $8,613.18 |
DisclosureSEC source: 0001209191-20-044313 · doc4.xml · nonDerivative · entry 7 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 591,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $26.39, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 22:51 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,673 | $26.06 | $147,838.38 |
DisclosureSEC source: 0001209191-20-044313 · doc4.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 591,926 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.31 to $26.30, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 22:51 UTC |
Payson NormanDirector
|
SaleCommon Stock | 327 | $26.34 | $8,613.18 |
DisclosureSEC source: 0001209191-20-044313 · doc4.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 591,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $26.39, inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 22:51 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,673 | $26.06 | $147,838.38 |
DisclosureSEC source: 0001209191-20-044313 · doc4.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 591,926 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.31 to $26.30, inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 16:34 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 16,100 | $26.34 | $424,143.23 |
DisclosureSEC source: 0001387131-20-006949 · ownership.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,844,018 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.15 to $26.70 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 18,798,075 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F5 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F6 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 22:51 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,500 | $26.07 | $117,315.00 |
DisclosureSEC source: 0001209191-20-044313 · doc4.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 719,000 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.78 to $26.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (6) and (7) herein. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 22:51 UTC |
Payson NormanDirector
|
SaleCommon Stock | 6,000 | $26.07 | $156,420.00 |
DisclosureSEC source: 0001209191-20-044313 · doc4.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 597,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.78 to $26.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (6) and (7) herein. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 22:51 UTC |
Payson NormanDirector
|
SaleCommon Stock | 6,000 | $26.07 | $156,420.00 |
DisclosureSEC source: 0001209191-20-044313 · doc4.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 597,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.78 to $26.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (6) and (7) herein. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 24, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · derivative · entry 10 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,002 Underlying: Common Stock · 16,000 shares Expires 2029-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option vested on June 3, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 24, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
SaleCommon Stock | 9,005 | $26.95 | $242,684.75 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · nonDerivative · entry 3 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,044 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 22, 2020. Read SEC document |
| July 24, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Tax withholdingCommon Stock | 6,995 | $26.79 | $187,396.05 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · nonDerivative · entry 2 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,049 Read SEC document |
| July 24, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Exercise / conversionCommon Stock | 16,000 | $3.96 | $63,360.00 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · nonDerivative · entry 1 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 274 | $27.52 | $7,540.48 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 12 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 723,500 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $27.70, inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 2,457 | $26.88 | $66,044.16 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 11 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 723,774 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.32 to $27.295, inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 1,769 | $25.98 | $45,958.62 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 10 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 726,231 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.32 to $26.31, inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 363 | $27.52 | $9,989.76 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 9 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 603,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $27.70, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 3,277 | $26.88 | $88,085.76 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 8 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 603,962 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.32 to $27.295, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 2,360 | $25.98 | $61,312.80 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 7 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 607,239 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.32 to $26.31, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 363 | $27.52 | $9,989.76 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 603,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $27.70, inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 3,277 | $26.88 | $88,085.76 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 603,962 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.32 to $27.295, inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 2,360 | $25.98 | $61,312.80 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 607,239 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.32 to $26.31, inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 22, 2020 Filed Jul 24, 2020 16:35 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 22,380 | $25.72 | $575,606.89 |
DisclosureSEC source: 0001387131-20-006717 · pgny-form4_072420.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,860,118 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.40 to $26.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 18,860,118 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F4 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| July 22, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,500 | $25.69 | $115,605.00 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 728,000 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.37 to $25.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (6), (7) and (8) herein. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 22, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 6,000 | $25.69 | $154,140.00 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 609,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.37 to $25.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (6), (7) and (8) herein. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 22, 2020 Filed Jul 24, 2020 20:54 UTC |
Payson NormanDirector
|
SaleCommon Stock | 6,000 | $25.69 | $154,140.00 |
DisclosureSEC source: 0001209191-20-043615 · doc4.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 609,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.37 to $25.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (6), (7) and (8) herein. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 16:31 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 28,317 | $26.45 | $748,891.20 |
DisclosureSEC source: 0001387131-20-006604 · pgny-form4_072020.xml · nonDerivative · entry 3 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,882,498 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.19 to $26.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 18,882,498 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F6 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 16:31 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 26,421 | $25.95 | $685,535.12 |
DisclosureSEC source: 0001387131-20-006604 · pgny-form4_072020.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,910,815 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.68 to $26.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 18,882,498 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F6 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 16:31 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 62,882 | $26.11 | $1,641,993.65 |
DisclosureSEC source: 0001387131-20-006604 · pgny-form4_072020.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,937,236 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.615 to $26.54 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 18,882,498 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F6 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 28 | $26.31 | $736.68 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 12 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 732,500 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,472 | $25.74 | $115,109.28 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 11 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 732,528 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $26.17 inclusive. F6 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 36 | $26.31 | $947.16 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 10 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 615,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,964 | $25.74 | $153,513.36 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 9 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 615,635 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $26.17 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 36 | $26.31 | $947.16 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 8 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 615,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,964 | $25.74 | $153,513.36 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 7 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 615,635 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $26.17 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 356 | $25.83 | $9,195.48 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 737,000 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.755 to $25.98 inclusive. F6 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,144 | $25.44 | $105,423.36 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 737,356 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.76 to $25.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (7). F6 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 474 | $25.83 | $12,243.42 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 621,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.755 to $25.98 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,526 | $25.44 | $140,581.44 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 622,073 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.76 to $25.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (7). F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 474 | $25.83 | $12,243.42 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 621,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.755 to $25.98 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:33 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,526 | $25.44 | $140,581.44 |
DisclosureSEC source: 0001209191-20-042858 · doc4.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 622,073 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.76 to $25.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (7). F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:36 UTC |
Anevski PeterPres., Chief Fin & Op. Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,940 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-20-042458 · doc4.xml · derivative · entry 6 Anevski Peter · CIK 0001576147 · Pres., Chief Fin & Op. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,675,636 Underlying: Common Stock · 24,940 shares Expires 2029-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option vested on May 23, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:36 UTC |
Anevski PeterPres., Chief Fin & Op. Officer
|
SaleCommon Stock | 24,940 | $27.74 | $691,835.60 |
DisclosureSEC source: 0001209191-20-042458 · doc4.xml · nonDerivative · entry 4 Anevski Peter · CIK 0001576147 · Pres., Chief Fin & Op. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,466,135 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.70 to $27.80 inclusive. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:36 UTC |
Anevski PeterPres., Chief Fin & Op. Officer
|
Exercise / conversionCommon Stock | 24,940 | $3.96 | $98,762.40 |
DisclosureSEC source: 0001209191-20-042458 · doc4.xml · nonDerivative · entry 3 Anevski Peter · CIK 0001576147 · Pres., Chief Fin & Op. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,491,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2020 Filed Jul 15, 2020 00:36 UTC |
Anevski PeterPres., Chief Fin & Op. Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,444 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-20-042458 · doc4.xml · derivative · entry 5 Anevski Peter · CIK 0001576147 · Pres., Chief Fin & Op. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700,576 Underlying: Common Stock · 4,444 shares Expires 2029-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option vested on May 23, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 10, 2020 Filed Jul 15, 2020 00:36 UTC |
Anevski PeterPres., Chief Fin & Op. Officer
|
SaleCommon Stock | 4,444 | $27.70 | $123,098.80 |
DisclosureSEC source: 0001209191-20-042458 · doc4.xml · nonDerivative · entry 2 Anevski Peter · CIK 0001576147 · Pres., Chief Fin & Op. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,466,135 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $27.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| July 10, 2020 Filed Jul 15, 2020 00:36 UTC |
Anevski PeterPres., Chief Fin & Op. Officer
|
Exercise / conversionCommon Stock | 4,444 | $3.96 | $17,598.24 |
DisclosureSEC source: 0001209191-20-042458 · doc4.xml · nonDerivative · entry 1 Anevski Peter · CIK 0001576147 · Pres., Chief Fin & Op. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,470,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 20:44 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,500 | $25.74 | $115,830.00 |
DisclosureSEC source: 0001209191-20-042175 · doc4.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 741,500 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.24 to $26.12 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 20:44 UTC |
Payson NormanDirector
|
SaleCommon Stock | 6,000 | $25.74 | $154,440.00 |
DisclosureSEC source: 0001209191-20-042175 · doc4.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 627,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.24 to $26.12 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 20:44 UTC |
Payson NormanDirector
|
SaleCommon Stock | 6,000 | $25.74 | $154,440.00 |
DisclosureSEC source: 0001209191-20-042175 · doc4.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 627,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.24 to $26.12 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.